Anna Wiernicka

BACKGROUND: Treatment options for patients with mild to moderate ulcerative colitis (UC) failing 5ASA are limited. MH002 is an optimized consortium of 6 nonpathogenic, well characterized commensal bacteria with immunomodulating, wound healing and gut barrier protective effects…